A carregar...
The systemic implication of novel non-statin therapies in cardiovascular diabetology: PCSK9 as a case model
PCSK9, like other novel non-statin drugs were primarily developed to help patients achieve low-density lipoprotein cholesterol targets, especially in patients with dyslipidemia not achieving lipid goals with statins due to poor tolerance or inadequate response. PCSK9 inhibitors, in addition to modul...
Na minha lista:
| Publicado no: | Cardiovasc Endocrinol Metab |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Wolters Kluwer Health
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7673769/ https://ncbi.nlm.nih.gov/pubmed/33225229 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/XCE.0000000000000204 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|